Gifu, Japan

Mitsuo Ninomiya

This inventor holds 1 USPTO granted patent. Top assignee: Yasutoshi Muto. Active years: 1998.


% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mitsuo Ninomiya: Innovator in Anticarcinogenic Drug Composition

Introduction

Mitsuo Ninomiya is a notable inventor based in Gifu, Japan. He has made significant contributions to the field of medicine, particularly in the development of anticarcinogenic drug compositions. His work aims to combat various forms of cancer, showcasing his dedication to improving health outcomes.

Latest Patents

Mitsuo Ninomiya holds a patent for an anticarcinogenic drug composition. This invention effectively inhibits the recurrence of hepatocellular carcinoma and addresses the occurrence of other cancers such as cervical carcinoma intraepitheliale, lung adenocarcinoma, and mammary tumors. The composition is notable for its high safety profile and contains 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid or a salt thereof. He has 1 patent to his name.

Career Highlights

Throughout his career, Mitsuo Ninomiya has focused on innovative solutions to combat cancer. His research has led to advancements in drug compositions that are both effective and safe for patients. His work is a testament to his commitment to medical innovation.

Collaborations

Mitsuo Ninomiya has collaborated with notable colleagues, including Yasutoshi Muto and Hisataka Moriwaki. These partnerships have contributed to the development and refinement of his inventions.

Conclusion

Mitsuo Ninomiya's contributions to the field of anticarcinogenic drug compositions highlight his role as an important inventor in the medical community. His innovative work continues to pave the way for advancements in cancer treatment.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…